[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 796 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 796

To amend the Federal Food, Drug, and Cosmetic Act to require a warning 
label advising that the effects of mifepristone can be counteracted, to 
 amend the Public Health Service Act to establish a hotline to provide 
information to women seeking to counteract the effects of mifepristone, 
                        and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                            January 28, 2025

Mrs. Miller of Illinois (for herself, Mr. Babin, Mr. Moore of Alabama, 
  Mr. Moore of West Virginia, Mr. Ogles, Mr. Webster of Florida, Ms. 
  Tenney, Mr. Clyde, Mr. Harris of Maryland, and Mr. Weber of Texas) 
 introduced the following bill; which was referred to the Committee on 
                          Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To amend the Federal Food, Drug, and Cosmetic Act to require a warning 
label advising that the effects of mifepristone can be counteracted, to 
 amend the Public Health Service Act to establish a hotline to provide 
information to women seeking to counteract the effects of mifepristone, 
                        and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Second Chance for Moms Act of 
2025''.

SEC. 2. MIFEPRISTONE WARNING LABEL AND HOTLINE.

    (a) Warning Label.--
            (1) In general.--Section 502 of the Federal Food, Drug, and 
        Cosmetic Act (21 U.S.C. 352) is amended by adding at the end 
        the following:
    ``(hh) If it is the drug mifepristone, and its labeling does not 
bear the following statement printed in conspicuous text: `WARNING: 
Medical evidence suggests that the abortifacient effects of 
mifepristone can be counteracted by natural progesterone, which can 
increase the chance of fetal survival. The American Society for 
Reproductive Medicine has determined that natural progesterone is safe 
in the first trimester of pregnancy. For more information, call [___].' 
(with the blank filled in to refer to the appropriate number for the 
hotline under section 1009 of the Public Health Service Act).''.
            (2) Effective date.--Section 502(hh) of the Federal Food, 
        Drug, and Cosmetic Act (as added by paragraph (1)) applies 
        beginning on the date that is 6 months after the date of 
        enactment of this Act.
    (b) Hotline.--Title X of the Public Health Service Act (42 U.S.C. 
300 et seq.) is amended by adding at the end the following:

``SEC. 1009. HOTLINE FOR REVERSAL OF EFFECTS OF MIFEPRISTONE.

    ``(a) In General.--The Secretary shall establish or maintain, 
directly or by grant or contract, a toll-free hotline to provide 
support for 24 hours a day, 7 days a week, for women seeking to reverse 
the effects of the drug mifepristone.
    ``(b) Referrals to APR Providers Only.--A referral through the 
hotline described in subsection (a) may only be made to a health care 
provider that provides abortion pill reversal services.''.
                                 <all>